WinstonWınston
Back
Avanos Medical logo

Avanos Medical

AVNS
26
Medical - Devices · Healthcare
Winston Score
26
Winston is worried
Below-average fundamentals — multiple weak pillars.
Data as of Aug 23, 2026 · filings through Mar 31, 2026
How the score breaks down
Quality
Mixed
Growth
Mixed
Cash Flow
Weak
Stability
Good
Valuation
Data not available

Winston Score History

The full picture

Avanos Medical is a medical device company that makes products to help patients manage pain and recover from illness or surgery. Its main products include nerve block systems for pain relief, feeding tubes, and airway management devices used in hospitals and clinics. The company spun off from Halyard Health in 2018 and focuses on what it calls "pure-play" pain management and recovery solutions.

Avanos earns money by selling these medical devices to hospitals, surgery centers, and healthcare providers, primarily in the United States but also in some international markets. The company generates roughly $700–800 million in annual revenue, but its negative operating and return margins show it is currently spending more than it earns from operations. The key challenge ahead is returning to profitability while facing competition from larger medical device companies like Medtronic and Becton Dickinson, which have significantly more resources and broader product portfolios.

Politician Trades

1 trades / 12mo

0 Congressional buys and 1 sell on AVNS in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+8.8% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

-21.4% YoY

YoY Growth Rate

Earnings declining

Insider Activity

1.8%ownership

Flat

Insider ownership roughly steady over the past year

Cash Runway

~12 months

$66M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Adequate runway but may need to raise capital within 2 years

Growth context

Avanos Medical is growing revenue at 9% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
48.5%
Healthy — 48.5% gross margin
Profit after running costs
Operating Margin
6.7%
Modest — 6.7% operating margin
Return on the money invested
ROCE
-6.4%
Weak — -6.4% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+3.9%
Slow sales growth (+3.9% YoY)
Profit growth
EPS YoY
N/A
Data not available
How steady the profit is
EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
Data not available
Spare cash per sale
FCF Margin
1.0%
Thin free cash flow (1.0%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.14
Conservative — low debt load (0.14)
Covers its interest
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
no trend
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial